Source BioScience signals growth with opening of new Cambridge Genomics and Precision Medicine unit
Source BioScience has celebrated the opening of its new Cambridge Genomics and Precision Medicine unit.
The company, a laboratory service partner, said the new facility at Vision Park in Histon would strengthen its offer to the life science industry.
It has been involved in the Cambridge ecosystem for more than 20 years, and supports academic institutions including the University of Cambridge, biotechs, pharmaceutical companies and other life science organisations of all sizes with research and development.
Jay LeCoque, chairman and CEO of Source BioScience, part of SourceBio International Ltd, said: “Our investment in this state-of-the-art facility is a strong commitment to growing our genomics and precision medicine laboratory service portfolio and to strengthen our world class offering the life sciences need at this exciting time for genomic research and medicine.”
With UKAS and ISO 15189 and 9001 accreditations, Source BioScience offers a broad portfolio of services, and helped the Department of Health and Social Care and the UK government during the pandemic as a key Covid-19 testing laboratory.
It can help organisations with next generation sequencing (NGS), Sanger sequencing, bioinformatics and a range of molecular genetic services, using technologies including Illumina Novaseq, NextSeq500, MiSeq and Oxford Nanopore Technologies.
Its new laboratories and offices, designed and built by Thackray, represent a commitment to growing its genomics division.
Richard Stevens, director of genomics at Source BioScience, said: “The expansion of our Cambridge footprint will allow us to go from strength to strength in partnering with pharmaceutical, academic and biotech organisations to help them achieve their research goals quickly and efficiently, especially when combined with our stellar team of laboratory scientists.”
Following the launch of the new site last Thursday (February 16), at which guests enjoyed a tour of the laboratories, the company confirmed that it is planning to increase its headcount and introduce new technologies.
The company also has sites in London, Chichester, Rochdale and Nottingham, Tramore in Ireland and San Diego in the US.
